Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...
Rolling Out10h
5 health issues that make vaping extraordinarily risky
Discover why doctors warn against vaping for people with these five health conditions including asthma, heart disease, and ...
Daily13h
Inhaled Therapy with Ensifentrine Significantly may Reduce COPD Exacerbations, unravels research
A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions ...